Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival

Cancer

Volumn 113, Issue 11, 2008, Pages 3181-3185

  Borthakur, Gautam ^a   Kantarjian, Hagop ^a   Wang, Xuemei ^a   Plunkett Jr , William K ^a   Gandhi, Varsha V ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Ravandi, Farhad ^a   Pierce, Sherry ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ara C; Core binding factor; Fludarabine; GCSF

Indexed keywords

ANTINEOPLASTIC AGENT; CORE BINDING FACTOR; CYTARABINE; DRUG DERIVATIVE; FLAG PROTOCOL; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; UNCLASSIFIED DRUG; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CORE BINDING FACTORS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; VIDARABINE;

EID: 58149220896     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23927     Document Type: Article

References (23)

1. Erickson P, Gao J, Chang KS, et al. Identification of break-points in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825-1831.
2. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041-1044. (Pubitemid 23300863)
3. Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087-1094. (Pubitemid 41095042)
4. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006; 135:165-173. (Pubitemid 44401613)
5. Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia. 1998;12:1482-1490.
6. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741-3750. (Pubitemid 41102131)
7. Plunkett W, Liliemark JO, Adams TM, et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987;47:3005- 3011.
8. Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony- stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995;1:169-178.
9. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-124. (Pubitemid 23059984)
10. Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988;48:329-334. (Pubitemid 18045766)
11. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara- C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575-3583.
12. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99:3517-3523. (Pubitemid 34534517)
13. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv/ t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102: 462-469. (Pubitemid 36841961)
14. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649. (Pubitemid 46594039)
15. Kaplan E, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
17. Cox D. Regression models and life tables (with discussion). J R Stat Soc. 1972;B34:187-220.
18. Therneau T, Grambchs P. Modeling Survival Data. New York: Springer; 2000.
19. Venebales W, Ripley B. Modern Applied Statistics With Splus, 3rd ed. New York: Springer; 1999.
20. Lunn D, Thomas A, Best N, Siegelhalter D. WinBUGS-a Bayesian modeling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325-337.
21. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63-73. (Pubitemid 43996625)
22. Schnittger S, Schoch C. Quantitative PCR based minimal residual disease detection in core binding factor leukemias: prognostication and guiding of therapy. Leuk Res. 2006;30: 657-658.
23. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003;102:2746-2755. (Pubitemid 37248843)